

# Beshay N Zordoky

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6873230/publications.pdf>

Version: 2024-02-01

60  
papers

2,396  
citations

218677

26  
h-index

223800

46  
g-index

65  
all docs

65  
docs citations

65  
times ranked

3748  
citing authors

#	ARTICLE	IF	CITATIONS
1	Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 1155-1177.	3.8	252
2	Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013, 1832, 1723-1733.	3.8	167
3	Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. , 2010, 125, 446-463.		154
4	Role of NF- $\kappa$ B in the Regulation of Cytochrome P450 Enzymes. <i>Current Drug Metabolism</i> , 2009, 10, 164-178.	1.2	152
5	Metabolomic Fingerprint of Heart Failure with Preserved Ejection Fraction. <i>PLoS ONE</i> , 2015, 10, e0124844.	2.5	150
6	Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E243-E253.	3.5	105
7	Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. <i>Toxicology and Applied Pharmacology</i> , 2010, 242, 38-46.	2.8	95
8	Modulation of Cytochrome P450 Gene Expression and Arachidonic Acid Metabolism during Isoproterenol-Induced Cardiac Hypertrophy in Rats. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2277-2286.	3.3	94
9	H9c2 cell line is a valuable in vitro model to study the drug metabolizing enzymes in the heart. <i>Journal of Pharmacological and Toxicological Methods</i> , 2007, 56, 317-322.	0.7	91
10	The anti-proliferative effect of metformin in triple-negative MDA-MB-231 breast cancer cells is highly dependent on glucose concentration: Implications for cancer therapy and prevention. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 1943-1957.	2.4	77
11	Acute Doxorubicin Toxicity Differentially Alters Cytochrome P450 Expression and Arachidonic Acid Metabolism in Rat Kidney and Liver. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1440-1450.	3.3	71
12	Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure. <i>Current Drug Metabolism</i> , 2008, 9, 122-128.	1.2	68
13	AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism. <i>Cardiovascular Research</i> , 2015, 107, 235-245.	3.8	67
14	3-Methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. <i>British Journal of Pharmacology</i> , 2009, 158, 1808-1819.	5.4	59
15	Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity. <i>Biology of Sex Differences</i> , 2018, 9, 38.	4.1	50
16	Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. <i>Pharmacological Research</i> , 2010, 61, 410-418.	7.1	46
17	Soluble epoxide hydrolase inhibitor, <sc>TUPS</sc>, protects against isoprenaline-induced cardiac hypertrophy. <i>British Journal of Pharmacology</i> , 2013, 168, 1794-1807.	5.4	44
18	AMPK-Dependent Inhibitory Phosphorylation of ACC Is Not Essential for Maintaining Myocardial Fatty Acid Oxidation. <i>Circulation Research</i> , 2014, 115, 518-524.	4.5	43

#	ARTICLE	IF	CITATIONS
19	Induction of several cytochrome P450 genes by doxorubicin in H9c2 cells. <i>Vascular Pharmacology</i> , 2008, 49, 166-172.	2.1	42
20	Role of cytochrome P450-mediated arachidonic acid metabolites in the pathogenesis of cardiac hypertrophy. <i>Drug Metabolism Reviews</i> , 2013, 45, 173-195.	3.6	41
21	Co-administration of resveratrol with doxorubicin in young mice attenuates detrimental late-occurring cardiovascular changes. <i>Cardiovascular Research</i> , 2018, 114, 1350-1359.	3.8	41
22	Chronic Doxorubicin Cardiotoxicity Modulates Cardiac Cytochrome P450-Mediated Arachidonic Acid Metabolism in Rats. <i>Drug Metabolism and Disposition</i> , 2012, 40, 2126-2135.	3.3	40
23	Determination of the Dominant Arachidonic Acid Cytochrome P450 Monooxygenases in Rat Heart, Lung, Kidney, and Liver: Protein Expression and Metabolite Kinetics. <i>AAPS Journal</i> , 2013, 15, 112-122.	4.4	39
24	Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 104-105, 8-17.	1.9	36
25	Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice. <i>Biology of Sex Differences</i> , 2017, 8, 1.	4.1	35
26	2,3,7,8-Tetrachlorodibenzo-p-dioxin and 1 <sup>2</sup> -naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. <i>Toxicology in Vitro</i> , 2010, 24, 863-871.	2.4	31
27	Resveratrol reduces cardiac NLRP3-inflammasome activation and systemic inflammation to lessen doxorubicin-induced cardiotoxicity in juvenile mice. <i>FEBS Letters</i> , 2021, 595, 1681-1695.	2.8	30
28	Inhibition of Soluble Epoxide Hydrolase Confers Cardioprotection and Prevents Cardiac Cytochrome P450 Induction by Benzo(a)pyrene. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 273-281.	1.9	28
29	Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology. <i>Nutrients</i> , 2019, 11, 627.	4.1	27
30	Acute arsenic toxicity alters cytochrome P450 and soluble epoxide hydrolase and their associated arachidonic acid metabolism in C57Bl/6 mouse heart. <i>Xenobiotica</i> , 2012, 42, 1235-1247.	1.1	26
31	Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence. , 2021, 221, 107751.		22
32	Sexual dimorphism of acute doxorubicin-induced nephrotoxicity in C57Bl/6 mice. <i>PLoS ONE</i> , 2019, 14, e0212486.	2.5	21
33	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. <i>PLoS ONE</i> , 2020, 15, e0232507.	2.5	21
34	CYP1B1 as a therapeutic target in cardio-oncology. <i>Clinical Science</i> , 2020, 134, 2897-2927.	4.3	21
35	The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity. <i>Cardio-Oncology</i> , 2016, 2, 4.	1.7	17
36	Anticancer effects of resveratrol in canine hemangiosarcoma cell lines. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 253-261.	1.8	17

#	ARTICLE	IF	CITATIONS
37	Acute arsenic treatment alters cytochrome P450 expression and arachidonic acid metabolism in lung, liver and kidney of C57Bl/6 mice. <i>Xenobiotica</i> , 2013, 43, 719-729.	1.1	16
38	Cardiomyocyte specific adipose triglyceride lipase overexpression prevents doxorubicin induced cardiac dysfunction in female mice. <i>Heart</i> , 2013, 99, 1041-1047.	2.9	15
39	Sexual Dimorphism in Doxorubicin-induced Systemic Inflammation: Implications for Hepatic Cytochrome P450 Regulation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1279.	4.1	13
40	EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263. <i>Cells</i> , 2022, 11, 1992.	4.1	8
41	Cardiovascular ramifications of therapy-induced endothelial cell senescence in cancer survivors. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166352.	3.8	4
42	Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients. <i>BMC Veterinary Research</i> , 2021, 17, 378.	1.9	4
43	Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9023.	4.1	3
44	Divergent Cardiac Effects of Angiotensin II and Isoproterenol Following Juvenile Exposure to Doxorubicin. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 742193.	2.4	3
45	Resveratrol Prevents Hypertension and Cardiac Hypertrophy in Hypertensive Rodents. <i>Canadian Journal of Diabetes</i> , 2013, 37, S23.	0.8	2
46	Psychosocial stress unmasks latent doxorubicin-induced cardiotoxicity. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 124, 93-94.	1.9	2
47	Normoglycemia sensitizes MDA-MB-231 breast cancer cells to metformin through an AMPK-dependent mechanism (LB610). <i>FASEB Journal</i> , 2014, 28, LB610.	0.5	2
48	Response to Schoormans. <i>Journal of the National Cancer Institute</i> , 2021, 113, 214-215.	6.3	1
49	Metformin Modulates Doxorubicin-induced Senescence Phenotype in Endothelial Cells. <i>FASEB Journal</i> , 2021, 35, .	0.5	1
50	Acute Doxorubicin Toxicity Differentially Alters Cytochrome P450 Expression in the Kidney and Liver of Male Sprague Dawley Rats. <i>Free Radical Biology and Medicine</i> , 2010, 49, S75.	2.9	0
51	Sexually Dimorphic Regulation of Renal Soluble Epoxide Hydrolase by Acute Doxorubicin-induced Toxicity. <i>FASEB Journal</i> , 2019, 33, 678.8.	0.5	0
52	Abstract 266: Sex Differences in Anthracycline-Induced Cardiotoxicity in Young Mice. <i>Circulation Research</i> , 2019, 125, .	4.5	0
53	Doxorubicin Cardiotoxicity in Young Tumor-bearing Mice. <i>FASEB Journal</i> , 2020, 34, 1-1.	0.5	0
54	Abstract 411: Absence of Sexual Dimorphism in Isoproterenol-induced Cardiac Dysfunction in C57BL/6 Mice. <i>Circulation Research</i> , 2020, 127, .	4.5	0

#	ARTICLE	IF	CITATIONS
55	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
56	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
57	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
58	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
59	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0
60	Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction. , 2020, 15, e0232507.		0